Clinical Trial Update: Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma [Phase 2]

View source ↗

Summary

Phase II trial comparing pimasertib to dacarbazine in patients with N-Ras mutated locally advanced or metastatic malignant cutaneous melanoma has completed with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Cutaneous Melanoma
• Melanoma
• N-ras Mutated Melanoma

Drugs mentioned

• Dacarbazine (dacarbazine)
• Pimasertib (pimasertib)

Snippet

Sponsor: EMD Serono | Conditions: N-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2018-01-05